Stryker Will Discuss Rejected OP-1 PMA At Upcoming Meeting With FDA
This article was originally published in The Gray Sheet
Executive Summary
Stryker expects to meet with FDA by March 1 to discuss the agency's "not approvable" letter for OP-1 bone growth factor for treating nonunion fractures.